A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...